RT Journal Article
SR Electronic
T1 Molecular Stratification of Chronic Kidney Disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.09.21263234
DO 10.1101/2021.09.09.21263234
A1 Reznichenko, Anna
A1 Nair, Viji
A1 Eddy, Sean
A1 Tomilo, Mark
A1 Slidel, Timothy
A1 Ju, Wenjun
A1 Conway, James P.
A1 Badal, Shawn S.
A1 Wesley, Johnna
A1 Liles, John T.
A1 Moosmang, Sven
A1 Williams, Julie M.
A1 Quinn, Carol Moreno
A1 Bitzer, Markus
A1 Karihaloo, Anil
A1 Breyer, Matthew D.
A1 Duffin, Kevin L.
A1 Patel, Uptal D.
A1 Magnone, Maria Chiara
A1 Bhat, Ratan
A1 Kretzler, Matthias
YR 2021
UL http://medrxiv.org/content/early/2021/09/13/2021.09.09.21263234.abstract
AB Current classification of chronic kidney disease (CKD) into stages based on the indirect measures of kidney functional state, estimated glomerular filtration rate and albuminuria, is agnostic to the heterogeneity of underlying etiologies, histopathology, and molecular processes. We used genome-wide transcriptomics from patients’ kidney biopsies, directly reflecting kidney biological processes, to stratify patients from three independent CKD cohorts. Unsupervised Self-Organizing Maps (SOM), an artificial neural network algorithm, assembled CKD patients into four novel subgroups, molecular categories, based on the similarity of their kidney transcriptomics profiles. The unbiased, molecular categories were present across CKD stages and histopathological diagnoses, highlighting heterogeneity of conventional clinical subgroups at the molecular level. CKD molecular categories were distinct in terms of biological pathways, transcriptional regulation and associated kidney cell types, indicating that the molecular categorization is founded on biologically meaningful mechanisms. Importantly, our results revealed that not all biological pathways are equally activated in all patients; instead, different pathways could be more dominant in different subgroups and thereby differentially influencing disease progression and outcomes. This first kidney-centric unbiased categorization of CKD paves the way to an integrated clinical, morphological and molecular diagnosis. This is a key step towards enabling precision medicine for this heterogeneous condition with the potential to advance biological understanding, clinical management, and drug development, as well as establish a roadmap for molecular reclassification of CKD and other complex diseases.One sentence summary Unbiased grouping of patients based on kidney biopsy transcriptomics profiles generated a novel molecular categorization of chronic kidney disease.Competing Interest StatementDr. Kretzler reports grants from NIH, non-financial support from University of Michigan, during the conduct of the study; grants from JDRF, Astra-Zeneca, NovoNordisk, Eli Lilly, Gilead, Goldfinch Bio, Merck, Chan Zuckerberg Initiative, Janssen, Boehringer-Ingelheim, Moderna, Chinook, amfAR, Angion, RenalytixAI, Retrophin, European Union Innovative Medicine Initiative and Certa outside the submitted work; In addition, Dr. Kretzler has a patent PCT/EP2014/073413, Biomarkers and methods for progression prediction for chronic kidney disease, licensed. Dr. Eddy has served as co-Investigator on grants funded by Gilead Sciences, NovoNordisk, AstraZeneca, Jannsen and Eli Lilly. Dr. Patel serves on the Board of Directors of Kidney Health Initiative. All other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. A.R., T.S., J.P.C., S.M., J.M.W., R.B. are employees of AstraZeneca. S.S.B., J.T.L., U.P.D. are employees and J.T.L is a shareholder of Gilead. C.M.Q. is an employee of Vifor Pharma, J.W., A.K. are employees of NovoNordisk. K.L.D. is an employee and stockholder of Eli Lilly and Company. M.D.B., M.C.M. are employees, M.C.M is also a shareholder of Johnson and Johnson.Funding StatementThis work was done as part of Renal Precompetitive Consortium (RPC2) collaboration (60) and was jointly funded by the participating members. This work is supported, in part, by George M. OBrien Michigan Kidney Translational Core Center, funded by NIH/NIDDK grant P30-DK-081943. The Nephrotic Syndrome Study Network Consortium (NEPTUNE), U54-DK-083912, is a part of the National Institutes of Health (NIH) Rare Disease Clinical Research Network (RDCRN), supported through a collaboration between the Office of Rare Diseases Research, NCATS, and the National Institute of Diabetes, Digestive, and Kidney Diseases. Additional funding and/or programmatic support for this project has also been provided by the University of Michigan, the NephCure Kidney International and the Halpin Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study only uses publicly available data.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesERCB (European Renal cDNA Bank) data were accessed from GEO accession ID: GSE104954; C-PROBE (Clinical Phenotyping Resource and Biobank Core) tubulointerstitial transcriptomics data generated on Affymetrix Human Genome U133 Plus 2.0 Array were available for 42 patients (GEO accession ID: GSE69438). Affymetrix Human Gene 2.1 ST Array tubulointerstitial transcriptomics data from 107 NEPTUNE (Nephrotic Syndrome Study Network) adult CKD were accessed from GEO accession ID: GSE108112. Tubulointerstitial transcriptomics data from 46 living kidney donors were accessed from GEO accession ID:GSE104954.